ATE281469T1 - Inhibitor des wachstumsfaktors für gefäss- endothelzellen - Google Patents

Inhibitor des wachstumsfaktors für gefäss- endothelzellen

Info

Publication number
ATE281469T1
ATE281469T1 AT94911403T AT94911403T ATE281469T1 AT E281469 T1 ATE281469 T1 AT E281469T1 AT 94911403 T AT94911403 T AT 94911403T AT 94911403 T AT94911403 T AT 94911403T AT E281469 T1 ATE281469 T1 AT E281469T1
Authority
AT
Austria
Prior art keywords
growth factor
endothelial cells
vascular endothelial
inhibitor
vegf
Prior art date
Application number
AT94911403T
Other languages
English (en)
Inventor
Richard L Kendall
Kenneth A Thomas Jr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE281469T1 publication Critical patent/ATE281469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94911403T 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefäss- endothelzellen ATE281469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3876993A 1993-03-25 1993-03-25
PCT/US1994/001957 WO1994021679A1 (en) 1993-03-25 1994-02-25 Inhibitor of vascular endothelial cell growth factor

Publications (1)

Publication Number Publication Date
ATE281469T1 true ATE281469T1 (de) 2004-11-15

Family

ID=21901791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911403T ATE281469T1 (de) 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefäss- endothelzellen

Country Status (12)

Country Link
US (5) US5712380A (de)
EP (1) EP0694042B1 (de)
JP (1) JP3734262B2 (de)
AT (1) ATE281469T1 (de)
AU (1) AU684498B2 (de)
CA (1) CA2158745C (de)
DE (1) DE69434115T2 (de)
DK (1) DK0694042T3 (de)
ES (1) ES2230542T3 (de)
IL (1) IL109016A (de)
PT (1) PT694042E (de)
WO (1) WO1994021679A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2242227T5 (es) 1996-07-15 2011-12-09 Chugai Seiyaku Kabushiki Kaisha Nuevo factor de tipo vegf.
DE69736860T2 (de) * 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
EP1086705A4 (de) * 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk Inhibitoren der aktivität des vaskularen endothelialen wachstumsfaktors
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US20030191055A1 (en) * 1999-01-15 2003-10-09 Epstein Stephen E. Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
EP1263474A1 (de) * 2000-03-08 2002-12-11 Neurosearch A/S Verfahren zur sensibilisierung von endothelzellen für medikamentenvorstufen
IL154696A (en) 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US20030181377A1 (en) * 2002-02-12 2003-09-25 Vanderbilt University Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
US20040101478A1 (en) * 2002-03-29 2004-05-27 Thomas Kenneth A In vivo methods of determining activity of receptor-type kinase inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK2267021T3 (en) 2002-09-12 2015-03-30 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US7750138B2 (en) * 2004-06-08 2010-07-06 Chengdu Kanghong Biotechnologies Co. Ltd. Angiogenesis-inhibiting chimeric protein and the use
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
BRPI0515264B1 (pt) 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EP1855707B1 (de) * 2005-02-28 2012-04-04 Oncotherapy Science, Inc. Epitop peptide, die vom vascular endothelial growth factor rezeptor 1 abgeleitet wurden und impfstoffe, die diese enthalten
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
JP2009501521A (ja) * 2005-07-13 2009-01-22 ベス イスラエル ディーコネス メディカル センター 炎症応答を診断および処置する方法
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
EP2235529B1 (de) * 2008-01-07 2016-12-14 Ortho-Clinical Diagnostics, Inc. Bestimmung des sflt-1:angiogenesefaktorkomplexes
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
CA2930987A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
KR101844596B1 (ko) 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
EA201791939A1 (ru) 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
ES2908467T3 (es) 2016-04-29 2022-04-29 Adverum Biotechnologies Inc Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante
ES2916344T3 (es) 2016-06-16 2022-06-30 Adverum Biotechnologies Inc Composiciones y métodos para reducir la neovascularización ocular
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
KR102616820B1 (ko) 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019182683A1 (en) * 2018-03-22 2019-09-26 The Children's Medical Center Corporation Methods and compositions relating to lung repair
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
EP4349852A1 (de) 2021-05-28 2024-04-10 Shanghai Regenelead Therapies Co., Ltd. Rekombinantes adeno-assoziiertes virus mit veränderlichem kapsid und anwendung davon
AU2022383744A1 (en) * 2021-11-02 2024-05-02 Enumita As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221915T1 (de) * 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1

Also Published As

Publication number Publication date
IL109016A0 (en) 1994-06-24
AU684498B2 (en) 1997-12-18
US20090247460A1 (en) 2009-10-01
WO1994021679A1 (en) 1994-09-29
IL109016A (en) 2005-07-25
DE69434115D1 (de) 2004-12-09
DE69434115T2 (de) 2005-10-27
JP3734262B2 (ja) 2006-01-11
EP0694042B1 (de) 2004-11-03
US20030120038A1 (en) 2003-06-26
DK0694042T3 (da) 2005-02-14
CA2158745A1 (en) 1994-09-29
EP0694042A4 (de) 2001-05-02
CA2158745C (en) 2007-06-19
ES2230542T3 (es) 2005-05-01
US8034772B2 (en) 2011-10-11
US5861484A (en) 1999-01-19
EP0694042A1 (de) 1996-01-31
AU6393494A (en) 1994-10-11
US20070010442A1 (en) 2007-01-11
US5712380A (en) 1998-01-27
PT694042E (pt) 2005-02-28
US7071159B2 (en) 2006-07-04
JPH08508161A (ja) 1996-09-03

Similar Documents

Publication Publication Date Title
ATE281469T1 (de) Inhibitor des wachstumsfaktors für gefäss- endothelzellen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69918946D1 (de) Rezeptoren für il-18
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DE69434908D1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
EE9800353A (et) Pürasinoonidest trombiini inhibiitorid
PT1066380E (pt) Receptor de celula t soluvel
DK1140173T3 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
NZ516258A (en) Tek antagonists
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
ATE346869T1 (de) Agonistische antikörper gegen tie2
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
ATE287402T1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ES2057571T3 (es) Receptor de pdgf-alfa.
NO982715L (no) Endotel celle-proliferasjonsinhibitor og fremgangsmate for anvendelse
NZ514488A (en) Vascular endothelial cell growth factor variants and uses thereof
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
DE69033220D1 (de) Immunoassays für und monoklonale antikörper gegen prothrombin-aktivierende peptide und ihre abbauprodukte
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
WO1996023883A3 (en) Modified ligands for receptor tyrosine kinases
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
ES2196360T3 (es) Ensayo de western blot que sirve para la identificacion de anticuerpos especificos del virus cmvh.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0694042

Country of ref document: EP

REN Ceased due to non-payment of the annual fee